BR112023025188A2 - Métodos de uso de anticorpos anti-sortilina - Google Patents
Métodos de uso de anticorpos anti-sortilinaInfo
- Publication number
- BR112023025188A2 BR112023025188A2 BR112023025188A BR112023025188A BR112023025188A2 BR 112023025188 A2 BR112023025188 A2 BR 112023025188A2 BR 112023025188 A BR112023025188 A BR 112023025188A BR 112023025188 A BR112023025188 A BR 112023025188A BR 112023025188 A2 BR112023025188 A2 BR 112023025188A2
- Authority
- BR
- Brazil
- Prior art keywords
- sortilin
- methods
- antibodies
- sortilin antibodies
- matured
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208238P | 2021-06-08 | 2021-06-08 | |
| US202163209360P | 2021-06-10 | 2021-06-10 | |
| US202163225916P | 2021-07-26 | 2021-07-26 | |
| US202163277069P | 2021-11-08 | 2021-11-08 | |
| US202263304522P | 2022-01-28 | 2022-01-28 | |
| US202263311379P | 2022-02-17 | 2022-02-17 | |
| PCT/US2022/072827 WO2022261648A2 (en) | 2021-06-08 | 2022-06-08 | Methods of use of anti-sortilin antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023025188A2 true BR112023025188A2 (pt) | 2024-02-27 |
Family
ID=84426402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023025188A BR112023025188A2 (pt) | 2021-06-08 | 2022-06-08 | Métodos de uso de anticorpos anti-sortilina |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240132597A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4351728A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024526060A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023025188A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3220428A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022261648A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3618928T (lt) | 2018-07-13 | 2023-04-11 | Alector Llc | Anti-sortilino antikūnai ir jų panaudojimo būdai |
| WO2025031098A1 (zh) * | 2023-08-09 | 2025-02-13 | 瑞诺元(苏州)生物科技有限公司 | 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119679944A (zh) * | 2018-01-25 | 2025-03-25 | 渤健马萨诸塞州股份有限公司 | 治疗脊髓性肌萎缩症的方法 |
| EP3983441A1 (en) * | 2019-06-11 | 2022-04-20 | Alector LLC | Anti-sortilin antibodies for use in therapy |
-
2022
- 2022-06-08 CA CA3220428A patent/CA3220428A1/en active Pending
- 2022-06-08 EP EP22821249.4A patent/EP4351728A4/en not_active Withdrawn
- 2022-06-08 JP JP2023575534A patent/JP2024526060A/ja not_active Withdrawn
- 2022-06-08 BR BR112023025188A patent/BR112023025188A2/pt unknown
- 2022-06-08 WO PCT/US2022/072827 patent/WO2022261648A2/en not_active Ceased
-
2023
- 2023-12-07 US US18/532,382 patent/US20240132597A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024526060A (ja) | 2024-07-17 |
| EP4351728A4 (en) | 2025-08-27 |
| WO2022261648A3 (en) | 2023-01-19 |
| EP4351728A2 (en) | 2024-04-17 |
| US20240132597A1 (en) | 2024-04-25 |
| WO2022261648A2 (en) | 2022-12-15 |
| CA3220428A1 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022019892A2 (pt) | Métodos para tratar e/ou retardar a progressão de uma doença ou lesão e para monitorar o tratamento de um indivíduo | |
| CL2021003327A1 (es) | Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089). | |
| BR112021025077A2 (pt) | Anticorpos anti-sortilina para uso em terapia | |
| ZA202211057B (en) | Anti-trem2 antibodies and methods of use thereof | |
| CR20200566A (es) | Anticuerpos anti-sirpa y metodos de utilización de los mismos | |
| PH12019502463A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
| EA201791127A1 (ru) | Антитела, содержащие модифицированные константные участки тяжелой цепи | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| BR112018074847A2 (pt) | anticorpos específicos anti hla-g | |
| BR112022011570A2 (pt) | Anticorpos anti-mertk e métodos de uso dos mesmos | |
| BRPI0821658B8 (pt) | anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos | |
| WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
| WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| MX2020013324A (es) | Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos. | |
| EA201891178A1 (ru) | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения | |
| MX2021009975A (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer. | |
| BR112022001733A2 (pt) | Anticorpos anti-ms4a4a e métodos de uso dos mesmos | |
| BR112023025188A2 (pt) | Métodos de uso de anticorpos anti-sortilina | |
| MX2021000933A (es) | Anticuerpos anti-siglec-5 y métodos para su uso. | |
| MX2024010324A (es) | Metodos de uso de anticuerpos anti-trem2. | |
| BR112022003635A2 (pt) | Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso | |
| CL2022003296A1 (es) | Anticuerpos anti-cd200r1 y métodos de uso de los mismos | |
| BR112022011337A2 (pt) | Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo | |
| MX2022004058A (es) | Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo. | |
| AR122237A1 (es) | Anticuerpos anti-sortilina y métodos para su uso |